Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan

• Yamada, Kenji

• Shiraishi, Hideaki

• Oki, Eishin

• Ishige, Mika

• Fukao, Toshiyuki

• Hamada, Yusuke

• Sakai, Norio

• Ochi, Fumihiro

• Watanabe, Asami

• Kawakami, Sanae

• Kuzume, Kazuyo

• Watanabe, Kenji

• Sameshima, Koji

• NAKAMAGOE, Kiyotaka

• TAMAOKA, Akira

• Asahina, Naoko

• Yokoshiki, Saki

• Miyakoshi, Takashi

• Ono, Kota

• Oba, Koji

• Isoe, Toshiyuki

• Hayashi, Hiroshi

• Yamaguchi, Seiji

• Sato, Norihiro

Abstract

Introduction: Fatty acid oxidation disorders (FAODs) are rare diseases caused by defects in mitochondrial fatty acid oxidation (FAO) enzymes. While the efficacy of bezafibrate, a peroxisome proliferator-activated receptor agonist, on the in vitro FAO capacity has been reported, the in vivo efficacy remains controversial. Therefore, we conducted a clinical trial of bezafibrate in Japanese patients with FAODs. Materials and methods: This trial was an open-label, non-randomized, and multicenter study of bezafibrate treatment in 6 patients with very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency and 2 patients with carnitine palmitoyltransferase-II (CPT-2) deficiency (median age, 8.2 years; ranging from 5.8 to 26.4 years). Bezafibrate was administered for 6 months following a 6-month observation period. The primary endpoint was the frequency of myopathic attacks, and the secondary endpoints were serum acylcarnitines (ACs, C14:1 or C16 + C18:1), creatine kinase (CK) levels, degree of muscle pain (VAS; visual analog scale) during myopathic attacks, and quality of life (QOL; evaluated using validated questionnaires). Results: The frequency of myopathic attacks after bezafibrate administration decreased in 3 patients, increased in 3, and did not change in 2. The CK, AC, and VAS values during attacks could be estimated in only three or four patients, but a half of the patients did not experience attacks before or after treatment. Changes in CK, AC, and VAS values varied across individuals. In contrast, three components of QOL, namely, physical functioning, role limitation due to physical problems (role physical), and social functioning, were significantly elevated. No adverse drug reactions were observed. Conclusion: In this study, the frequency of myopathic attacks and CK, AC, and VAS values during the attacks could not be evaluated due to several limitations, such as a small trial population. Our findings indicate that bezafibrate improves the QOL of patients with FAODs, but its efficacy must be examined in future investigations.

Journal

• Molecular genetics and metabolism reports

  Molecular genetics and metabolism reports 15 55-63, 2018-06

  Elsevier

Keywords

• Bezafibrate
• Fatty acid oxidation disorders (FAODs)
• Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency
• Carnitine palmitoyltransferase-II (CPT-2) deficiency
• Clinical trial

Details

• CRID: 1050001202649398528
• NII Article ID: 120006491518
• DOI: 10.1016/j.ymgmr.2018.02.003
• ISSN: 22144269
• HANDLE: 2241/00152991
• HANDLE: 2115/71201
• Web Site: https://tsukuba.repo.nii.ac.jp/records/47623
• Web Site: https://api.elsevier.com/content/article/PII:S2214426918300077?httpAccept=text/xml
• Web Site: https://api.elsevier.com/content/article/PII:S2214426918300077?httpAccept=text/plain
• Text Lang: en
• Article Type: journal article
• Data Source:
  • IRDB
  • Crossref
  • CiNii Articles
  • KAKEN